CINPA1 is a selective inverse agonist of the Constitutive Androstane Receptor (CAR), a nuclear receptor that regulates xenobiotic metabolism, liver function, and cell proliferation. It is primarily researched for its therapeutic potential in liver cancer, where it inhibits CAR-mediated growth of hepatocellular carcinoma cells. Studies also explore its ability to overcome chemoresistance in cancer cells, enhancing the efficacy of chemotherapy. Beyond oncology, CINPA1 is investigated for modulating energy metabolism and treating metabolic disorders such as obesity and diabetes. Its applications are mainly in preclinical research to elucidate CAR signaling mechanisms and develop targeted therapies.